Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI Drops Flibanserin; BioSante Gets Excited

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer Ingelheim shuts down development of its female desire drug due to complications in the regulatory process.
Advertisement

Related Content

Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
HSDD Field To Itself, BioSante Has High Hopes For LibiGel
HSDD Field To Itself, BioSante Has High Hopes For LibiGel
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
Flibanserin Fails To Improve Sexual Desire, FDA Advisory Committee Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS071408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel